AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Satellos Bioscience Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SRK950
6.42▼ 0.21 (-3.09%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
6.63
Day's Range
6.42 – 6.73
52-Week Range
5.44 – 13.73
Volume
33.7K
Avg Volume
54.9K
Share Statistics
Shares Outstanding
Employees
21
Exchange
XNAS
Listed
2021-08-18
Share count as of December 31, 2025

Satellos Bioscience Inc. Common Stock (MSLE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Satellos Bioscience Inc. Common Stock (MSLE)
What is Satellos Bioscience Inc. Common Stock's Market Cap?
Satellos Bioscience Inc. Common Stock's Market Cap is $99.2M, based on as-reported figures from SEC (XBRL) filings.
What is Satellos Bioscience Inc. Common Stock's Enterprise Value?
Satellos Bioscience Inc. Common Stock's Enterprise Value is $84.0M, based on as-reported figures from SEC (XBRL) filings.
What is Satellos Bioscience Inc. Common Stock's Net Income (TTM)?
Satellos Bioscience Inc. Common Stock's Net Income (TTM) is -$24.9M, based on as-reported figures from SEC (XBRL) filings.
What is Satellos Bioscience Inc. Common Stock's Diluted EPS (TTM)?
Satellos Bioscience Inc. Common Stock's Diluted EPS (TTM) is -1.61, based on as-reported figures from SEC (XBRL) filings.
What is Satellos Bioscience Inc. Common Stock's Net Debt?
Satellos Bioscience Inc. Common Stock's Net Debt is -$15.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MSLEAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024
Consolidated Statements of Loss and Comprehensive Loss
Research and development ("R&D")
General and administrative ("G&A")
TOTAL OPERATING EXPENSES:
OTHER INCOME AND EXPENSES
Finance income
Impairment of intangible asset—
Loss on derivative financial instruments—
Foreign exchange gain
NET LOSS BEFORE INCOME TAXES
NET LOSS FOR THE YEAR